Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Genetic Basis for Vulnerability to Substance Abuse

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00247819
First received: October 31, 2005
Last updated: NA
Last verified: October 2005
History: No changes posted
  Purpose

This investigation seeks to better define the genetic basis for vulnerability to substance abuse.


Condition Intervention
Substance Abuse
Procedure: Blood draw

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Allelic Linkage in Substance Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 8000
Study Start Date: August 1992
Estimated Study Completion Date: February 2006
Detailed Description:

Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study.

This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Substance abusers
  • Allow for blood draw

Exclusion Criteria:

  • Cognitively impaired
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00247819

Contacts
Contact: Fred Snyder 410-550-1615 ext 23 fsnyder@mail.nih.gov
Contact: Sue Ruckel 410-550-1502 sruckel@mail.nih.gov

Locations
United States, Maryland
National Institute on Drug Abuse Recruiting
Baltimore, Maryland, United States, 21224
Contact: Fred Snyder    410-550-1615 ext 23    fsnyder@mail.nih.gov   
Contact: Sue Ruckel    410-550-1502    sruckel@mail.nih.gov   
Principal Investigator: George Uhl, M.D., Ph.D.         
Sponsors and Collaborators
Investigators
Principal Investigator: George Uhl, M.D., Ph.D. National Institute on Drug Abuse (NIDA)
  More Information

Publications:
Gelernter J, Moises H, Grandy D, et al. Exclusion of schizophrenia triat from regions of the D2 dopamine receptor and prophobilinogen deaminase genes. In: 28th Annual Meeting, American College of Neurophyschopharmacology, December 13, 1980; Maui, Hawaii, Abstracts p.216.
Wyatt RJ, Farouk K, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatric Annals 1988; 18:531-534.

ClinicalTrials.gov Identifier: NCT00247819     History of Changes
Other Study ID Numbers: NIDA-IRP-148
Study First Received: October 31, 2005
Last Updated: October 31, 2005
Health Authority: United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):
Substance abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on November 25, 2014